S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
NASDAQ:QURE

uniQure (QURE) Stock Forecast, Price & News

$13.72
+0.31 (+2.31%)
(As of 05/20/2022 04:00 PM ET)
Add
Compare
Today's Range
$13.01
$13.87
50-Day Range
$13.15
$20.45
52-Week Range
$12.52
$38.80
Volume
263,500 shs
Average Volume
524,127 shs
Market Capitalization
$640.01 million
P/E Ratio
1.99
Dividend Yield
N/A
Beta
1.13
30 days | 90 days | 365 days | Advanced Chart
Receive QURE News and Ratings via Email

Sign-up to receive the latest news and ratings for uniQure and its competitors with MarketBeat's FREE daily newsletter.

uniQure logo

About uniQure

uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Headlines

uniQure (NASDAQ:QURE) Downgraded by StockNews.com to "Sell"
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:QURE
Employees
463
Year Founded
N/A

Sales & Book Value

Annual Sales
$524 million
Cash Flow
$7.46 per share
Book Value
$11.70 per share

Profitability

Net Income
$329.59 million
Pretax Margin
62.22%

Debt

Price-To-Earnings

Miscellaneous

Free Float
45,407,000
Market Cap
$640.01 million
Optionable
Optionable

Company Calendar

Last Earnings
5/02/2022
Today
5/22/2022
Next Earnings (Estimated)
7/25/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

2.53 out of 5 stars

Medical Sector

112th out of 1,416 stocks

Pharmaceutical Preparations Industry

43rd out of 677 stocks

Analyst Opinion: 3.5Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 1.9 5 -4 -3 -2 -1 -













uniQure (NASDAQ:QURE) Frequently Asked Questions

Is uniQure a buy right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for uniQure in the last year. There are currently 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" uniQure stock.
View analyst ratings for uniQure
or view top-rated stocks.

When is uniQure's next earnings date?

uniQure is scheduled to release its next quarterly earnings announcement on Monday, July 25th 2022.
View our earnings forecast for uniQure
.

How were uniQure's earnings last quarter?

uniQure (NASDAQ:QURE) issued its earnings results on Monday, May, 2nd. The biotechnology company reported ($1.00) earnings per share for the quarter, missing the consensus estimate of ($0.93) by $0.07. uniQure had a net margin of 61.76% and a trailing twelve-month return on equity of 54.85%.
View uniQure's earnings history
.

What price target have analysts set for QURE?

8 brokers have issued twelve-month target prices for uniQure's shares. Their forecasts range from $27.46 to $66.00. On average, they expect uniQure's stock price to reach $48.81 in the next year. This suggests a possible upside of 255.7% from the stock's current price.
View analysts' price targets for uniQure
or view top-rated stocks among Wall Street analysts.

Who are uniQure's key executives?
uniQure's management team includes the following people:
  • Mr. Matthew Craig Kapusta, CEO & Exec. Director (Age 50, Pay $965.48k) (LinkedIn Profile)
  • Mr. Christian Klemt, CFO, Principal Financial Officer & GM of Amsterdam Site (Age 49, Pay $392.6k) (LinkedIn Profile)
  • Dr. Alexander E. Kuta Ph.D., Exec. VP of Quality & Regulatory (Age 62, Pay $652.58k)
  • Dr. Ricardo Dolmetsch Ph.D., Pres of R&D (Age 53, Pay $626.15k) (LinkedIn Profile)
  • Prof. Hugo Katus, Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany
  • Mr. Pierre Caloz, Chief Operating Officer
  • Mr. David Cerveny, Chief Legal Officer, Gen. Counsel & Sec. (Age 55)
  • Dr. Tamara Tugal Ph.D., MBA, Bus. Devel. Director
  • Ms. Erin Boyer, Chief People & Culture Office
  • Ms. Maria E. Cantor, Chief Corp. Affairs Officer (Age 54)
What is Matthew Kapusta's approval rating as uniQure's CEO?

8 employees have rated uniQure CEO Matthew Kapusta on Glassdoor.com. Matthew Kapusta has an approval rating of 74% among uniQure's employees.

What other stocks do shareholders of uniQure own?

Based on aggregate information from My MarketBeat watchlists, some companies that other uniQure investors own include Empire Resorts (NYNY), Micron Technology (MU), Gilead Sciences (GILD), Alibaba Group (BABA), AbbVie (ABBV), GW Pharmaceuticals (GWPH), NVIDIA (NVDA), Exelixis (EXEL), Square (SQ) and bluebird bio (BLUE).

What is uniQure's stock symbol?

uniQure trades on the NASDAQ under the ticker symbol "QURE."

Who are uniQure's major shareholders?

uniQure's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (9.36%), State Street Corp (6.03%), Vanguard Group Inc. (2.59%), JPMorgan Chase & Co. (1.90%), Bank of New York Mellon Corp (1.45%) and Federated Hermes Inc. (1.28%). Company insiders that own uniQure stock include Alexander Edward Kuta III, Christian Klemt, Leonard E Post, Matthew C Kapusta, Ricardo Dolmetsch and Robert Gut.
View institutional ownership trends for uniQure
.

Which major investors are selling uniQure stock?

QURE stock was sold by a variety of institutional investors in the last quarter, including Invesco Ltd., Federated Hermes Inc., Connor Clark & Lunn Investment Management Ltd., Bank of New York Mellon Corp, Henry James International Management Inc., Citigroup Inc., Jane Street Group LLC, and BNP Paribas Arbitrage SA. Company insiders that have sold uniQure company stock in the last year include Alexander Edward Kuta III, Christian Klemt, Leonard E Post, Matthew C Kapusta, Ricardo Dolmetsch, and Robert Gut.
View insider buying and selling activity for uniQure
or view top insider-selling stocks.

Which major investors are buying uniQure stock?

QURE stock was acquired by a variety of institutional investors in the last quarter, including State Street Corp, Assenagon Asset Management S.A., JPMorgan Chase & Co., Acadian Asset Management LLC, BlackRock Inc., Integral Health Asset Management LLC, UBS Group AG, and Robeco Institutional Asset Management B.V..
View insider buying and selling activity for uniQure
or or view top insider-buying stocks.

How do I buy shares of uniQure?

Shares of QURE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is uniQure's stock price today?

One share of QURE stock can currently be purchased for approximately $13.72.

How much money does uniQure make?

uniQure has a market capitalization of $640.01 million and generates $524 million in revenue each year. The biotechnology company earns $329.59 million in net income (profit) each year or $6.89 on an earnings per share basis.

How many employees does uniQure have?

uniQure employs 463 workers across the globe.

What is uniQure's official website?

The official website for uniQure is www.uniqure.com.

How can I contact uniQure?

uniQure's mailing address is PAASHEUVELWEG 25A, AMSTERDAM P7, 1105 BP. The biotechnology company can be reached via phone at (120) 240-6000, via email at [email protected], or via fax at 31-20-566-9272.

This page was last updated on 5/23/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.